Tumor-Associated Microbiome: Where Do We Stand?

Abstract

The study of the human microbiome in oncology is a growing and rapidly evolving field. In the past few years, there has been an exponential increase in the number of studies investigating associations of microbiome and cancer, from oncogenesis and cancer progression to resistance or sensitivity to specific anticancer therapies. The gut microbiome is now known to play a significant role in antitumor immune responses and in predicting the efficacy of immune-checkpoint inhibitors in cancer patients. Beyond the gut, the tumor-associated microbiome—microbe communities located either in the tumor or within its body compartment—seems to interact with the local microenvironment and the tumor immune contexture, ultimately impacting cancer progression and treatment outcome. However, pre-clinical research focusing on causality and mechanistic pathways as well as proof-of-concept studies are still needed to fully understand the potential clinical utility of microbiome in cancer patients. Moreover, there is a need for the standardization of methodology and the implementation of quality control across microbiome studies to allow for a better interpretation and greater comparability of the results reported between them. This review summarizes the accumulating evidence in the field and discusses the current and upcoming challenges of microbiome studies.

Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma

“…In RCC, gut microflora are definitely an important non-genetic contributing factor to the progression of the disease, as microbial populations in the gut of patients with RCC have been found to be distinct from their adjacent normal tissues ( 190 , 191 ). Gut microbiota can also modulate the tumor microenvironment (TME) by influencing the levels of various metabolites such as dietary amino acids and short-chain fatty acids, for example, butyrate, acetate, and propionate, which have an anti-inflammatory property ( 192 ).…”

Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review

“…Several strategies have been developed to analyze microbial expression in healthy subjects and cancer patients [74]. The first approach encompasses sequencing techniques, among which are high-throughput 16S ribosomal RNA gene amplicon sequencing (16S rRNAseq), and whole-shotgun metagenomics are the most frequently used.…”

Prospects and Challenges of the Study of Anti-Glycan Antibodies and Microbiota for the Monitoring of Gastrointestinal Cancer

“…Commensal microorganisms are crucial for the maintenance of local and systemic immune homeostasis, and disbalance of the commensal ecosystem resulting in dysbiosis [74]. Different taxa of tumour-associated microbiota are implicated in cancer pathogenesis and their diagnostic and prognostic potential have been assessed [84]. Dysregulated immune response in the tumour microenvironment and anticancer therapy-mediated systemic immunosuppression may also contribute to the colonisation of pathogens in tumours.…”